Traders should monitor upcoming regulatory interactions and pivotal trial initiation in Q4 2026. Given the strong Phase 2 data and needle-free advantage, any positive developments could drive significant upside in this small-cap biotech. Consider positioning ahead of pivotal study launch.
Price Chart
Executive Summary
Nasus Pharma announced positive Phase 2 results for its intranasal epinephrine candidate NS002, showing significantly faster epinephrine absorption compared to EpiPen®. The drug achieved a median time to therapeutic threshold of 1.69 minutes versus 3.42 minutes for EpiPen®, with strong performance across multiple dosing scenarios and no serious adverse events. The company plans to initiate a pivotal study in Q4 2026.
Key Facts
- NS002 achieved median T100 (time to 100 pg/mL epinephrine) of 1.69 minutes vs. 3.42 minutes for EpiPen® (p=0.033)
- At 5 minutes, 88.4% of NS002 patients reached therapeutic threshold vs. 64.6% for EpiPen®
- NS002 showed ~50% higher epinephrine exposure in the first 10 minutes compared to EpiPen®
- No serious adverse events reported; favorable safety profile confirmed
- Pivotal study planned for Q4 2026
Financial Impact
No direct financial figures disclosed, but successful pivotal trial could position NS002 as a major competitor in the multi-billion dollar anaphylaxis treatment market
Risk Factors
- Phase 2 success does not guarantee pivotal trial outcomes
- Regulatory hurdles for approval of a new epinephrine delivery method may be high
- Competition from established autoinjectors and potential generic entrants
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256155 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.51 | awaiting T+20 | — | $3.49 (−0.57%) |
Sep 23, 2026 4w ago | 3 | $3.64 $3.06 | ▼ −15.93% | ▼ −16.62% | $3.49 (−4.12%) |
Sep 18, 2026 5w ago | 424B5 | $3.44 $3.21 | ▲ +6.83% | ▲ +5.92% | $3.49 (−1.45%) |
Sep 14, 2026 6w ago | 6-K | $3.65 $3.32 | ▼ −9.04% | ▼ −11.30% | $3.49 (−4.38%) |
Sep 14, 2026 6w ago | EFFECT | $3.65 $3.32 | ▼ −9.04% | ▼ −11.30% | $3.49 (−4.38%) |
Aug 21, 2026 9w ago | EFFECT | $4.00 $3.44 | ▼ −14.00% | ▼ −13.47% | $3.49 (−12.75%) |
Aug 19, 2026 9w ago | 6-K | $3.84 $3.53 | ▼ −8.07% | ▼ −6.12% | $3.49 (−9.11%) |
Aug 17, 2026 10w ago | 6-K | $3.70 $3.59 | ▼ −2.97% | ▼ −1.00% | $3.49 (−5.68%) |
Aug 17, 2026 10w ago | Press Release | $3.70 $3.59 | ▼ −2.97% | ▼ −1.00% | $3.49 (−5.68%) |
Apr 1, 2026 29w ago | EFFECT | $2.55 $2.56 | ▼ −0.39% | ▲ +9.33% | $3.49 (−36.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers